The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

Avalere Health was the most successful agency, winning three Golds, a Silver and the highly contested accolade of PMi Agency ...

European equities traded in the US as American depositary receipts were heading lower late Friday morning, declining 0.89% to 1,913.67 on the S&P Europe Select ADR Index, which is ...

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

The experimental program aims to align President Donald Trump’s most-favored-nation drug price targets with the prices charged to state Medicaid programs.

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...